CYTK - Cytokinetics Inc

-

$undefined

N/A

(N/A)

Cytokinetics Inc NasdaqGS:CYTK Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Location: 350 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.cytokinetics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

3.713B

Cash

938.2M

Avg Qtr Burn

-99.5M

Short % of Float

13.13%

Insider Ownership

0.77%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Aficamten Details
Obstructive hypertrophic cardiomyopathy (oHCM)

PDUFA

Approval decision

Aficamten Details
Hypertrophic cardiomyopathies

Phase 3

Data readout

Omecamtiv Mecarbil (cardiac myosin activator) Details
Pancreatic cancer, Heart disease, Heart failure

Phase 3

Data readout

Aficamten Details
Hypertrophic cardiomyopathies

Phase 3

Data readout

Aficamten Details
Hypertrophic cardiomyopathies

Phase 3

Update

Phase 2

Data readout

Phase 1

Data readout

CK-3828136 (CK-136) (cardiac troponin activator) Details
Heart failure, Heart disease, Epilepsy

Phase 1

Update

Failed

Discontinued